BrainStorm (BCLI) appoints ex-FDA official before ALS trial

BrainStorm Cell Therapeutics (BCLI) has appointed a former FDA official to its board in preparation for an upcoming trial focused on amyotrophic lateral sclerosis (ALS). This strategic move is aimed at strengthening the company's regulatory compliance and enhancing its clinical trial processes. The trial's success would be significant in advancing BrainStorm's product pipeline and could impact investor confidence and market valuation. The exact timeline for the trial was not disclosed, but such appointments often indicate proactive leadership in navigating regulatory challenges.